4-amino-1-(6-methyl-pyridin-3-ylmethyl)-6-(tetrahydro-pyran-4-ylmethoxy)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one | 1114529-49-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 4-amino-1-(6-methyl-pyridin-3-ylmethyl)-6-(tetrahydro-pyran-4-ylmethoxy)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one
• 英文别名: 4-Amino-1,3-dihydro-1-[(6-methyl-3-pyridinyl)methyl]-6-[(tetrahydro-2H-pyran-4-yl)methoxy]-2H-imidazo[4,5-c]-pyridin-2-one；4-amino-1-[(6-methylpyridin-3-yl)methyl]-6-(oxan-4-ylmethoxy)-3H-imidazo[4,5-c]pyridin-2-one
• CAS: 1114529-49-5
• 化学式: C₁₉H₂₃N₅O₃
• 分子量: 369.423
• InChiKey: DIGKZBFXEHAQBV-UHFFFAOYSA-N

物化性质

• 密度：
  1.305±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-amino-1-(6-methyl-pyridin-3-ylmethyl)-6-(tetrahydro-pyran-4-ylmethoxy)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one 在 盐酸 作用下， 以 水 、 乙腈 为溶剂， 反应 0.75h， 生成 4-amino-1-(6-methyl-pyridin-3-ylmethyl)-6-(tetrahydro-pyran-4-ylmethoxy)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one hydrochloride
  参考文献：
  名称：

  [EN] IMIDAZOPYRIDINONES
  [FR] IMIDAZOPYRIDINONES

  摘要：

  公开号：

  WO2009019553A3
• 作为产物：
  描述：

  4-氨基-2,6-二氯吡啶 在 硫酸 、 palladium on carbon 、 Me-THF 、 氨 、 氢气 、 硝酸 、 potassium carbonate 、 溶剂黄146 、 三乙胺 、 sodium iodide 作用下， 以 四氢呋喃 、 乙醇 、 丙酮 、 乙腈 为溶剂， 80.0 ℃ 、275.8 kPa 条件下， 生成 4-amino-1-(6-methyl-pyridin-3-ylmethyl)-6-(tetrahydro-pyran-4-ylmethoxy)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one
  参考文献：
  名称：

  Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection

  摘要：

  The synthesis and structure-activity relationships of a series of novel interferon inducers are described. Pharmacokinetic studies and efficacy assessment of a series of 8-oxo-3-deazapurine analogues led to the identification of compound 33, a potent and selective agonist of the TLR7 receptor with an excellent in vivo efficacy profile in a mouse model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.092

文献信息

• Imidazopyridinones
  申请人：Jones Peter H.

  公开号：US20110039884A1

  公开（公告）日：2011-02-17

  The invention relates to imidazopyridinones, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. By activating TLRs, it should be possible to induce or stimulate immune cells to mount an immune response. In particular, the TLR7 has been implicated in viral infections (such as HCV or HBV), cancers and tumours, and T2 Helper cell (TH2) mediated diseases, and hence TLR7 agonists are potentially useful in the treatment of such diseases. We have now found a series of imidazopyridinones which are agonists of TLR7. According, there is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is 3- to 8-membered saturated heterocyclic group wherein one ring member is —O—; and R 2 is phenyl or pyridinyl, each optionally substituted by C 1 -C 6 alkyl.

  本发明涉及咪唑吡啶酮及其在医药上的应用，包括含有它们的组合物、制备它们的过程以及用于这些过程中的中间体。通过激活TLRs，应该能够诱导或刺激免疫细胞产生免疫反应。特别是，TLR7已经被牵涉到病毒感染（如HCV或HBV）、癌症和肿瘤以及T2辅助细胞（TH2）介导的疾病，因此TLR7激动剂在这些疾病的治疗中具有潜在的用途。我们现在发现了一系列咪唑吡啶酮，它们是TLR7的激动剂。因此，提供了式（I）的化合物或其药学上可接受的盐或溶剂，其中R1是3-至8-成员的饱和杂环基团，其中一个环成员是—O—；R2是苯基或吡啶基，每个都可以选择地被C1-C6烷基取代。
• IMIDAZOPYRIDINONES
  申请人：JONES Peter H.

  公开号：US20090221631A1

  公开（公告）日：2009-09-03

  The invention relates to imidazopyridinones, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. By activating TLRs, it should be possible to induce or stimulate immune cells to mount an immune response. In particular, the TLR7 has been implicated in viral infections (such as HCV or HBV), cancers and tumours, and T2 Helper cell (TH2) mediated diseases, and hence TLR7 agonists are potentially useful in the treatment of such diseases. We have now found a series of imidazopyridinones which are agonists of TLR7. According, there is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is 3- to 8-membered saturated heterocyclic group wherein one ring member is —O—; and R 2 is phenyl or pyridinyl, each optionally substituted by C 1 -C 6 alkyl.

  本发明涉及咪唑吡啶酮及其在医学上的应用，包括含有它们的组合物，制备这些化合物的过程以及用于这些过程的中间体。通过激活TLRs，可以诱导或刺激免疫细胞产生免疫反应。特别是，TLR7已被认为与病毒感染（如丙型肝炎病毒或乙型肝炎病毒）、癌症和肿瘤以及T2辅助细胞（TH2）介导的疾病有关，因此TLR7激动剂在治疗这些疾病方面具有潜在的用途。我们现在发现了一系列咪唑吡啶酮，它们是TLR7的激动剂。因此，提供了式（I）的化合物或其药学上可接受的盐或溶剂，其中R1是3-至8-成员的饱和杂环基团，其中一个环成员为—O—；而R2是苯基或吡啶基，每个基团都可以选择性地被C1-C6烷基取代。
• Aspartic Protease Inhibitors
  申请人：Baldwin John J.

  公开号：US20100048636A1

  公开（公告）日：2010-02-25

  The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.

  本发明涉及天冬氨酸蛋白酶抑制剂。本发明所述的某些天冬氨酸蛋白酶抑制剂可以用以下结构式或其药学上可接受的盐来表示。本发明还涉及包括所述天冬氨酸蛋白酶抑制剂的药物组合物。本发明还涉及在需要拮抗一种或多种天冬氨酸蛋白酶的主体中的方法，以及使用所述天冬氨酸蛋白酶抑制剂治疗天冬氨酸蛋白酶介导的疾病的方法。
• Coating of artificial surfaces of medical aids and instruments, and cleaning and/or pretreatment of catheters and other medical aids and instruments
  申请人：Perzborn Elisabeth

  公开号：US20100003542A1

  公开（公告）日：2010-01-07

  The present invention relates to the use of factor Xa (FXa) inhibitors with anticoagulant action for the antithrombotic coating and/or treatment of artificial surfaces of medical aids and/or devices for the prevention of fibrin deposits and/or formation of blood clots and of thrombi, and the use of FXa inhibitors in the cleaning and/or pretreatment of catheters and other medical aids and devices.
• US8487108B2
  申请人：——

  公开号：US8487108B2

  公开（公告）日：2013-07-16